Gene transfer to skeletal muscle by site-specific delivery of electroporation and ultrasound

Biochemical and Biophysical Research Communications

Volumn 424, Issue 2, 2012, Pages 203-207

  Li, Yuanli ^a   Wang, Junqing ^a   Satterle, Andrew ^b   Wu, Qunqiang ^a   Wang, Jue ^c   Liu, Feng ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Electroporation; Gene delivery; Gene therapy; Skeletal muscle; US

Indexed keywords

ADENOVIRUS VECTOR; DNA; MEMBRANE METALLOENDOPEPTIDASE; NAKED DNA;

ALZHEIMER DISEASE; CELL MEMBRANE POTENTIAL; ELECTRIC CURRENT; ELECTRODE; ELECTROPORATION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; IN VIVO GENE TRANSFER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SINE WAVE CURRENT PULSE; SKELETAL MUSCLE; SYRINGE; ULTRASOUND; VIRAL GENE DELIVERY SYSTEM;

ALZHEIMER DISEASE; ANIMALS; DNA; ELECTRICITY; ELECTRODES; ELECTROPORATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MUSCLE, SKELETAL; NEPRILYSIN; NERVE GROWTH FACTORS; PLASMIDS; SONICATION; SYRINGES; TRANSFECTION;

EID: 84864318364     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.090     Document Type: Short Survey

References (58)

1. Stieger K., Lorenz B. The treatment of inherited dystrophies and neovascular disorders of the retina by rAAV-mediated gene therapy. Klin. Monbl. Augenheilkd. 2008, 225:1009-1023.
2. Gardlik R., Behuliak M., Palffy R., Celec P., Li C.J. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther. 2011, 18:425-431.
3. McMenamin M.M., Wood M.J. Progress and prospects: immunobiology of gene therapy for neurodegenerative disease: prospects and risks. Gene Ther. 2010, 17:448-458.
4. Zinkernagel M.S., McMenamin P.G., Forrester J.V., Degli-Esposti M.A. T cell responses in experimental viral retinitis: mechanisms, peculiarities and implications for gene therapy with viral vectors. Progr. Retin. Eye Res. 2011, 30:275-284.
5. Friedmann T., Roblin R. Gene therapy for human genetic disease?. Science 1972, 175:949-955.
6. Gene therapy clinical trials database, J.Gene Med. Available from. http://www.wiley.com/legacy/wileychi/genmed/clinical.
7. Vandenberghe L.H., Auricchio A. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther. 2012, 19:162-168.
8. Simonelli F., Maguire A.M., Testa F., Pierce E.A., Mingozzi F., Bennicelli J.L., Rossi S., Marshall K., Banfi S., Surace E.M., Sun J., Redmond T.M., Zhu X., Shindler K.S., Ying G.S., Ziviello C., Acerra C., Wright J.F., McDonnell J.W., High K.A., Bennett J., Auricchio A. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 2010, 18:643-650.
9. Fischer A., Hacein-Bey-Abina S., Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat. Immunol. 2010, 11:457-460.
10. Ferrua F., Brigida I., Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr. Opin. Allergy Clin. Immunol. 2010, 10:551-556.
11. Cartier N., Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 2010, 20:857-862.
12. Tilemann L., Ishikawa K., Weber T., Hajjar R.J. Gene therapy for heart failure. Circ. Res. 2012, 110:777-793.
13. Nilsson P., Iwata N., Muramatsu S., Tjernberg L.O., Winblad B., Saido T.C. Gene therapy in Alzheimer's disease - potential for disease modification. J. Cell. Mol. Med. 2010, 14:741-757.
14. Rodnitzky R.L. Upcoming treatments in Parkinson's disease, including gene therapy. Parkinsonism Relat. Disord. 2012, 18(Suppl 1):S37-S40.
15. Kohn D.B., Candotti F. Gene therapy fulfilling its promise. N. Engl. J. Med. 2009, 360:518-521.
16. Gomez-Manzano C., Jiang H., Alonso M., Yung W.K., Fueyo J. Gene therapy. Handb. Clin. Neurol. 2012, 104:331-338.
17. H. Boulaiz, J.A. Marchal, J. Prados, C. Melguizo, A. Aranega, Non-viral and viral vectors for gene therapy, Cell Mol Biol (Noisy-le-grand) 51 (2005) 3-22.
18. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., Batshaw M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80:148-158.
19. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
20. Pacak C.A., Walter G.A., Gaidosh G., Bryant N., Lewis M.A., Germain S., Mah C.S., Campbell K.P., Byrne B.J. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol. Ther. 2007, 15:1775-1781.
21. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., Delaere P., Branellec D., Schwartz B., Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. USA 1999, 96:4262-4267.
22. Murakami T., Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr. Gene Ther. 2011, 11:447-456.
23. Zolochevska O., Xia X., Williams B.J., Ramsay A., Li S., Figueiredo M.L. Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum. Gene Ther. 2011, 22:1537-1550.
24. Featherstone C. Electroporation: an effective technique for drug delivery and gene therapy. Am. Biotechnol. Lab. 1993, 11:16.
25. Heller L.C., Heller R. In vivo electroporation for gene therapy. Hum. Gene Ther. 2006, 17:890-897.
26. Schertzer J.D., Lynch G.S. Plasmid-based gene transfer in mouse skeletal muscle by electroporation. Meth. Mol. Biol. 2008, 433:115-125.
27. Goldspink G. Skeletal muscle as an artificial endocrine tissue. Best Pract. Res. Clin. Endocrinol. Metab. 2003, 17:211-222.
28. Danko I., Fritz J.D., Jiao S., Hogan K., Latendresse J.S., Wolff J.A. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Ther. 1994, 1:114-121.
29. Lu Q.L., Bou-Gharios G., Partridge T.A. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 2003, 10:131-142.
30. Muramatsu T., Nakamura A., Park H.M. In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals (review). Int. J. Mol. Med. 1998, 1:55-62.
31. Roche J.A., Ford-Speelman D.L., Ru L.W., Densmore A.L., Roche R., Reed P.W., Bloch R.J. Physiological and histological changes in skeletal muscle following in vivo gene transfer by electroporation. Am. J. Physiol. Cell Physiol. 2011, 301:C1239-C1250.
32. Liu F., Huang L. A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol. Ther. 2002, 5:323-328.
33. Satkauskas S., Bureau M.F., Puc M., Mahfoudi A., Scherman D., Miklavcic D., Mir L.M. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol. Ther. 2002, 5:133-140.
34. Durieux A.C., Bonnefoy R., Busso T., Freyssenet D. In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J. Gene Med. 2004, 6:809-816.
35. Wallace M.S., Ridgeway B., Jun E., Schulteis G., Rabussay D., Zhang L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: an evaluation of skin anesthesia. Reg. Anesth. Pain Med. 2001, 26:229-238.
36. Tjelle T.E., Salte R., Mathiesen I., Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006, 24:4667-4670.
37. Liu F., Sag D., Wang J., Shollenberger L.M., Niu F., Yuan X., Li S.D., Thompson M., Monahan P. Sine-wave current for efficient and safe in vivo gene transfer. Mol. Ther. 2007, 15:1842-1847.
38. Zderic V. Ultrasound-enhanced drug and gene delivery: a review. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2008, 2008:4472.
39. Passineau M.J., Zourelias L., Machen L., Edwards P.C., Benza R.L. Ultrasound-assisted non-viral gene transfer to the salivary glands. Gene Ther. 2010, 17:1318-1324.
40. Xenariou S., Griesenbach U., Liang H.D., Zhu J., Farley R., Somerton L., Singh C., Jeffery P.K., Ferrari S., Scheule R.K., Cheng S.H., Geddes D.M., Blomley M., Alton E.W. Use of ultrasound to enhance nonviral lung gene transfer in vivo. Gene Ther. 2007, 14:768-774.
41. Paliwal S., Mitragotri S. Ultrasound-induced cavitation: applications in drug and gene delivery. Expet Opin. Drug Deliv. 2006, 3:713-726.
42. Yang H., Liu Z.H., Liu Y.Y., Lou C.C., Ren Z.L., Miyoshi H. Vascular gene transfer and drug delivery in vitro using low-frequency ultrasound and microbubbles. Acta Pharmacol. Sin. 2010, 31:515-522.
43. Taniyama Y., Azuma J., Rakugi H., Morishita R. Plasmid DNA-based gene transfer with ultrasound and microbubbles. Curr. Gene Ther. 2011, 11:485-490.
44. Mayer C.R., Geis N.A., Katus H.A., Bekeredjian R. Ultrasound targeted microbubble destruction for drug and gene delivery. Expet Opin. Drug Deliv. 2008, 5:1121-1138.
45. Takeuchi D., Sato N., Shimamura M., Kurinami H., Takeda S., Shinohara M., Suzuki S., Kojima M., Ogihara T., Morishita R. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008, 15:561-571.
46. Alter J., Sennoga C.A., Lopes D.M., Eckersley R.J., Wells D.J. Microbubble stability is a major determinant of the efficiency of ultrasound and microbubble mediated in vivo gene transfer. Ultrasound Med. Biol. 2009, 35:976-984.
47. Xenariou S., Liang H.D., Griesenbach U., Zhu J., Farley R., Somerton L., Singh C., Jeffery P.K., Scheule R.K., Cheng S.H., Geddes D.M., Blomley M., Alton E.W. Low-frequency ultrasound increases non-viral gene transfer to the mouse lung. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42:45-51.
48. Li Y.S., Davidson E., Reid C.N., McHale A.P. Optimising ultrasound-mediated gene transfer (sonoporation) in vitro and prolonged expression of a transgene in vivo: potential applications for gene therapy of cancer. Cancer Lett. 2009, 273:62-69.
49. Li Y., Wang J., Grebogi C., Foote M., Liu F. A syringe-focused ultrasound device for simultaneous injection of DNA and gene transfer. J. Gene Med. 2012, 14:54-61.
50. Federici T., Boulis N.M. Gene-based treatment of motor neuron diseases. Muscle Nerve 2006, 33:302-323.
51. Jerusalinsky D., Baez M.V., Epstein A.L. Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases. J. Physiol. (Paris) 2012, 106:2-11.
52. Bergen J.M., Park I.K., Horner P.J., Pun S.H. Nonviral approaches for neuronal delivery of nucleic acids. Pharm. Res. 2008, 25:983-998.
53. Hellstrom-Lindahl E., Ravid R., Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol. Aging 2008, 29:210-221.
54. El-Amouri S.S., Zhu H., Yu J., Marr R., Verma I.M., Kindy M.S. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am. J. Pathol. 2008, 172:1342-1354.
55. Guan H., Liu Y., Daily A., Police S., Kim M.H., Oddo S., LaFerla F.M., Pauly J.R., Murphy M.P., Hersh L.B. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J. Neurosci. Res. 2009, 87:1462-1473.
56. Liu Y., Studzinski C., Beckett T., Guan H., Hersh M.A., Murphy M.P., Klein R., Hersh L.B. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol. Ther. 2009, 17:1381-1386.
57. Fischer D., Fahr A. Non-viral gene transfer medicinal products. Therapy with synthetic vectors. Pharmmazie Unserer Zeit 2011, 40:212-219.
58. Li Y., Wang J., Liu J., Liu F. A novel system for in vivo neprilysin gene delivery using a syringe electrode. J. Neurosci. Meth. 2010, 193:226-231.